Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

The study supports prior research that found the same thing.

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new ...

Research has found that weight-loss drugs such as Ozempic may help curb addictive behaviours, such as alcohol addiction. One ...

Weight loss drugs like Ozempic gained popularity for managing obesity, diabetes, and related chronic conditions, a new study ...

Newsweek has contacted Ozempic manufacturer Novo Nordisk for ... Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis. JAMA Neurology.

Diabetes and weight loss treatments such as Ozempic and Wegovy, known as GLP-1 agonists, could significantly reduce the risk of developing any type of dementia, according to a meta-analysis of 26 ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.